Cue Biopharma CUE 深 滬
已收盤 08-07 16:00:00 美东时间
27.12
+0.110
+0.41%
華盛通- 最 高27.60
- 今 開27.42
- 成交量 5.74万股
- 最 低 26.865
- 昨 收 27.01
- 總市值 1.14亿
- 52周最高 45.50
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 4.971
- 委 比 -90.48%
- 總股本 420.03万
- 歷史最高 950.70
- 量 比 0.26
- 振 幅 2.72%
- 歷史最低 4.971
- 每 手 1
- 風險率 8.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer Shao-Lee Lin, ...
08-03 20:33
Cue Biopharma Announces $50 Million Private Placement
Cue Biopharma ( ($CUE) ) has issued an announcement. On July 9, 2026, Cue Bioph...
07-11 05:57
Cue Biopharma to raise $50M in oversubscribed private placement
Cue Biopharma (CUE) has entered into a definitive securities purchase agreement to raise approximately $50.0M in gross proceeds through a private placement with a group of accredited institutional inv...
07-10 16:08
Cue Biopharma Announces $50.0 Million Private Placement
Cue Biopharma, a clinical-stage biopharma company, has secured approximately $50 million through a private placement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments. The funds will support clinical development and general corporate purposes. The company aims to advance therapies targeting functional cures for immunological disorders. The private placement is expected to close on July 13, 2026,...
07-10 01:40
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma announced the transition of its board, with four independent directors resigning, and the appointment of Daniel Camardo and Viola Meehan. Camardo, a former CEO with a track record of successful drug launches, and Meehan, a seasoned CFO with expertise in strategic finance, will bring critical experience to support the company's growth and late-stage clinical capabilities. The company emphasized their contributions to advancing transf...
06-02 20:05
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies for immunological disorders, announced that its CEO, Shao-Lee Lin, will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City. A live audio webcast and replay of the presentation will be available through Cue Biopharma’s Investor Relations website for 90 days. Cue Biopharma is a...
05-21 20:05
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.10) by 1100 percent. This is a 78.18 percent increase over losses of $(4.95) per share from the
05-15 05:24
Watching Cue Biopharma; Fugazi Research Issues Report On Co. Titled "$CUE: Reverse Splits, PIPE Dilution, and the Illusion of Recovery"
https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution
05-11 21:42
